Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

Copy For Citation

Beksac M., Seval G. C., PAYDAŞ S., Tuglular T. F., Arslan O., GÖKER H., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.10, 2019 (SCI-Expanded)

• Publication Type: Article / Abstract
• Volume: 19 Issue: 10
• Publication Date: 2019
• Doi Number: 10.1016/j.clml.2019.09.402
• Journal Name: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Erciyes University Affiliated: No